Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cixutumumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Cixutumumab - Eli Lilly and Company

Alternative Names: A12; IMC-A12; LY3012217; NSC 742460

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly and Company; ImClone Systems; M. D. Anderson Cancer Center; National Cancer Institute (USA)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action IGF type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant thymoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 06 Sep 2018 Discontinued - Phase-II for Head and neck cancer (Combination therapy, Neoadjuvant therapy) in USA (IV) (Eli Lilly pipeline, September 2018)
  • 06 Sep 2018 Discontinued - Phase-II for Head and neck cancer (Neoadjuvant therapy, Monotherapy) in USA (IV) (Eli Lilly pipeline, September 2018)
  • 01 May 2018 ImClone terminates a phase II trial in Colorectal cancer (Combination therapy, Metastatic disease) due to business reasons in USA (IV) (NCT00845039)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top